Articles by Kyle M. Rose, MD
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.